Ardelyx Funding & Investors
Fremont, CA
Ardelyx, Inc. manufactures biotechnological drugs. The Company offers pharmaceuticals to correct mineral metabolism imbalance and metabolic disorders by modulating the function of specific transporters, channels, and receptors located on the epithelia of the gastrointestinal tract. Ardelyx serves patients in the United States.
ardelyx.comTotal Amount Raised: $557,675,328
Ardelyx Funding Rounds
Post Ipo Debt
$20,000,000
Post Ipo Debt Investors
Healthcare Royalty PartnersKyowa Kirin Co.Post Ipo Debt
$27,500,000
Post Ipo Debt Investors
SLR Capital PartnersPost Ipo Equity
$125,000,000
Post Ipo Debt
$50,000,000
Post Ipo Equity
$110,000,000
Post Ipo Equity Investors
New Enterprise Associates (NEA)Quadrille CapitalEcoR1 CapitalRa Capital ManagementFirst Manhattan Consulting GroupRock Springs CapitalCormorant Asset ManagementPerceptive AdvisorsDeerfield ManagementDafna Capital ManagementPost Ipo Equity
$86,300,000
Post Ipo Equity
$77,771,627
Post Ipo Equity Investors
New Enterprise Associates (NEA)Ra Capital ManagementBroadfin CapitalCormorant Asset ManagementForesite CapitalRock Springs CapitalSabby CapitalIPO
Unknown
IPO
Unknown
Series B
$30,000,000
Series B Investors
AmgenCMEA CapitalNew Enterprise Associates (NEA)Debt Financing
$5,013,694
Series A
$26,090,000
Series A Investors
CMEA CapitalSeries A
$26,090,000
Series A Investors
CMEA Capital
Funding info provided by Diffbot.